For: | Mukaida N, Nakamoto Y. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma. World J Gastroenterol 2018; 24(17): 1839-1858 [PMID: 29740200 DOI: 10.3748/wjg.v24.i17.1839] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v24/i17/1839.htm |
Number | Citing Articles |
1 |
Wenjie Han, Ning Li, Jun Liu, Yongchen Sun, Xi Yang, Yu Wang. MicroRNA-26b-5p enhances T cell responses by targeting PIM-2 in hepatocellular carcinoma. Cellular Signalling 2019; 59: 182 doi: 10.1016/j.cellsig.2018.11.011
|
2 |
Olorunseun O Ogunwobi, Trisheena Harricharran, Jeannette Huaman, Anna Galuza, Oluwatoyin Odumuwagun, Yin Tan, Grace X Ma, Minhhuyen T Nguyen. Mechanisms of hepatocellular carcinoma progression. World Journal of Gastroenterology 2019; 25(19): 2279-2293 doi: 10.3748/wjg.v25.i19.2279
|
3 |
Neda Minaei, Roya Ramezankhani, Atena Tamimi, Abbas Piryaei, Ali Zarrabi, Amir Reza Aref, Ebrahim Mostafavi, Massoud Vosough. Immunotherapeutic approaches in Hepatocellular carcinoma: Building blocks of hope in near future. European Journal of Cell Biology 2023; 102(1): 151284 doi: 10.1016/j.ejcb.2022.151284
|
4 |
Yue Shi, Xiaoping Men, Xueting Li, Zhicun Yang, Hongjuan Wen. Research progress and clinical prospect of immunocytotherapy for the treatment of hepatocellular carcinoma. International Immunopharmacology 2020; 82: 106351 doi: 10.1016/j.intimp.2020.106351
|
5 |
Jia-Xi Mao, Wen-Yuan Guo, Meng Guo, Cong Liu, Fei Teng, Guo-Shan Ding. Acute rejection after liver transplantation is less common, but predicts better prognosis in HBV-related hepatocellular carcinoma patients. Hepatology International 2020; 14(3): 347 doi: 10.1007/s12072-020-10022-4
|
6 |
Jianing Ma, Yuning Xin, Qiang Wang, Lijuan Ding. Roles of cGAS-STING Pathway in Radiotherapy Combined with Immunotherapy for Hepatocellular Carcinoma. Molecular Cancer Therapeutics 2024; 23(4): 447 doi: 10.1158/1535-7163.MCT-23-0373
|
7 |
Pil Soo Sung, Jeong Won Jang. Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications. International Journal of Molecular Sciences 2018; 19(11): 3648 doi: 10.3390/ijms19113648
|
8 |
Hui Wei, Jing Yang, Xia Chen, Mengxiao Liu, Huiyun Zhang, Weiming Sun, Yuping Wang, Yongning Zhou. BAIAP2L2 is a novel prognostic biomarker related to migration and invasion of HCC and associated with cuprotosis. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-35420-0
|
9 |
Mohammed Abdul-Latif, Katherine Townsend, Charles Dearman, Kai-Keen Shiu, Khurum Khan. Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives. Cancer Treatment Reviews 2020; 88: 102030 doi: 10.1016/j.ctrv.2020.102030
|
10 |
Reza Mahjub, Sukhdeep Jatana, Suen Ern Lee, Zhu Qin, Griffin Pauli, Meysam Soleimani, Soheil Madadi, Shyh-Dar Li. Recent advances in applying nanotechnologies for cancer immunotherapy. Journal of Controlled Release 2018; 288: 239 doi: 10.1016/j.jconrel.2018.09.010
|
11 |
Valentina Leone, Adnan Ali, Achim Weber, Darjus Felix Tschaharganeh, Mathias Heikenwalder. Liver Inflammation and Hepatobiliary Cancers. Trends in Cancer 2021; 7(7): 606 doi: 10.1016/j.trecan.2021.01.012
|
12 |
Mingzhen Zhou, Baorui Liu, Jie Shen. Immunotherapy for hepatocellular carcinoma. Clinical and Experimental Medicine 2022; 23(3): 569 doi: 10.1007/s10238-022-00874-5
|
13 |
Tanja Gerlza, Christina Trojacher, Nikola Kitic, Tiziana Adage, Andreas J. Kungl. Development of Molecules Antagonizing Heparan Sulfate Proteoglycans. Seminars in Thrombosis and Hemostasis 2021; 47(03): 316 doi: 10.1055/s-0041-1725067
|
14 |
Yujiao Zhou, Feifei Liu, Chengmin Li, Guo Shi, Xiaolei Xu, Xue Luo, Yuanling Zhang, Jingjie Fu, Aizhong Zeng, Limin Chen. Construction and Characterization of Adenovirus Vectors Encoding Aspartate-β-Hydroxylase to Preliminary Application in Immunotherapy of Hepatocellular Carcinoma. Journal of Immunology Research 2018; 2018: 1 doi: 10.1155/2018/9832467
|
15 |
Hsiang-chi Tseng, Wei Xiong, Saiaditya Badeti, Yan Yang, Minh Ma, Ting Liu, Carlos A. Ramos, Gianpietro Dotti, Luke Fritzky, Jie-gen Jiang, Qing Yi, James Guarrera, Wei-Xing Zong, Chen Liu, Dongfang Liu. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nature Communications 2020; 11(1) doi: 10.1038/s41467-020-18444-2
|
16 |
Changhoon Choi, Gyu Sang Yoo, Won Kyung Cho, Hee Chul Park. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World Journal of Gastroenterology 2019; 25(20): 2416-2429 doi: 10.3748/wjg.v25.i20.2416
|
17 |
Dan Chen, Xiaoting Li, Hui Li, Kai Wang, Xianghua Tian, Jimei Wang. Identification of Immune-Related Prognostic mRNA and lncRNA in Patients with Hepatocellular Carcinoma. Journal of Oncology 2022; 2022: 1 doi: 10.1155/2022/5313149
|
18 |
Changpei Cheng, Qiyang Shou, Jiali Lang, Lu Jin, Xia Liu, Dongxin Tang, Zhu Yang, Huiying Fu. Gehua Jiecheng Decoction Inhibits Diethylnitrosamine-Induced Hepatocellular Carcinoma in Mice by Improving Tumor Immunosuppression Microenvironment. Frontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.00809
|
19 |
Rebekka Bent, Lorna Moll, Stephan Grabbe, Matthias Bros. Interleukin-1 Beta—A Friend or Foe in Malignancies?. International Journal of Molecular Sciences 2018; 19(8): 2155 doi: 10.3390/ijms19082155
|
20 |
Carina Hage, Sabine Hoves, Mailin Ashoff, Veronika Schandl, Stefan Hört, Natascha Rieder, Christian Heichinger, Marco Berrera, Carola H. Ries, Fabian Kiessling, Thomas Pöschinger, Roger Chammas. Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy. PLOS ONE 2019; 14(7): e0219517 doi: 10.1371/journal.pone.0219517
|
21 |
Min Yao, Wenli Sai, Wenjie Zheng, Li Wang, Zhizhen Dong, Dengfu Yao. Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth. Current Medicinal Chemistry 2020; 27(20): 3290 doi: 10.2174/0929867326666190624161158
|
22 |
Dan Peng, Yongqing Cai, Geng Chen, Min Hou, Xiaofeng Luo, Zhuoma Dongzhi, Hongjun Xie, Yao Liu. Efficacy and safety of apatinib versus sorafenib/placebo in first-line treatment for intermediate and advanced primary liver cancer: A systematic review and meta-analysis. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1101063
|
23 |
Ananya Ajith, Makram Merimi, Mandana Kazem Arki, Nikoo Hossein-khannazer, Mehdi Najar, Massoud Vosough, Etienne Marc Sokal, Mustapha Najimi. Immune regulation and therapeutic application of T regulatory cells in liver diseases. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1371089
|
24 |
Qingjia Chi, Di Wang, Ting Sun, Hua-Ping Liang. Integrated bioinformatical and in vitro study on drug targets for liver cirrhosis based on unsupervised consensus clustering and immune cell infiltration. Frontiers in Pharmacology 2023; 13 doi: 10.3389/fphar.2022.909668
|
25 |
Jingyu Xiao, Fei Wang, Xiaoyan Hu, Dongli Li, Geng Liu, Qumiao Xu, Chao Chen, Haitao Xiang, Xuan Dong, Linnan Zhu, Dishuang Yang, Yanan Gao, Meijuan Wang, Yonglun Luo, Cheng‐Chi Chao, Guanglei Li, Qiongyu Guo. Engineering In Vitro Organ‐Structured Tumor Model for Evaluating Neoantigen‐Specific T Cell Responses in Hepatocellular Carcinoma. Advanced Materials Interfaces 2023; 10(24) doi: 10.1002/admi.202300155
|